ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Appendicitis After Initiation of Tirzepatide.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A retrospective observational study on case reports of adverse drug reactions (ADRs) to tirzepatide.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tirzepatide is a GLP1/GIP receptor agonist that is used to treat type 2 diabetes and promote weight loss. Common side effects of Tirzepatide include nausea, vomiting, and diarrhea. More severe side effects include pancreatitis, cholelithiasis, thyroid cancer, and cholecystitis. With the increased use of these medications, additional side effects are being discovered. Delayed gastric emptying associated with GLP1/GIP receptor agonists can increase the risk of developing appendicitis due to changes in gastrointestinal motility. There is minimal data on the risk of developing appendicitis with Tirzepatide. This novel case report presents a 73-year-old female patient, without typical risk factors or obvious triggers, who developed appendicitis one week following the initiation of Tirzepatide. Once Tirzepatide was stopped, the patient's symptoms dramatically improved and there was improvement also demonstrated on CT imaging. The patient eventually got an outpatient appendectomy. Appendicitis is not frequently reported as a GLP1/GIP receptor agonist side effect in clinical studies. There seems to be a temporal association between Tirzepatide and the onset of appendicitis. This case report highlights the importance of considering appendicitis as a potential adverse effect of Tirzepatide, a GLP1/GIP receptor agonist.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.